TEL AVIV, Israel– QuantHealth, an AI-powered clinical trial design company that simulates clinical trials, today announced the appointment of Dr. Adam Petrich, MD, as the company’s inaugural Chief Medical Officer and Adam Goldberger as Chief Financial Officer.
Dr. Petrich, a medical oncologist and hematologist by training, has spent the last ten years in oncology drug development, including tenures of increasing responsibility at Daiichi-Sankyo and AbbVie, across various platforms and phases of clinical development. Prior to that, he was a full-time faculty member at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago. His role at QuantHealth will include enhancing product offerings and capabilities, providing oversight and guidance to the R&D teams, and leading all outward-facing clinically-oriented interactions.
As QuantHealth’s first Chief Financial Officer, Adam Goldberger will partner with the executive team to help drive innovation and reach critical financial milestones as the company continues commercializing its platform and expanding its roster of industry partners. Prior to QuantHealth, Adam spent more than two decades in various capacities within the private and public sectors, working for companies across Israel, The United States, and Australia. Most recently, he acted as Chief Business Officer at RenalSense and CFO/Group Executive at MedHealth.
“Having the right team in place is an essential component of ensuring QuantHealth becomes a ubiquitous piece of the drug discovery approval process,” said Orr Inbar, Co-founder and CEO of QuantHealth. “We couldn’t be more excited to have Dr. Petrich and Adam Goldberger joining us to help ensure the long-term scalability of our business while we continue to deliver the time efficiencies and cost savings the healthcare industry has come to expect from our trial simulations and synthetic trials.”
These new appointments come on the heels of QuantHealth securing a strategic investment from Accenture Ventures and participation from a leading CRO firm and additional investors, bringing its Series A funding total to $17M. QuantHealth was founded in 2020 with a mission to help pharmaceutical companies accelerate and de-risk their programs by using AI to simulate clinical trials. The company uses AI to deliver real-world evidence by predicting the end result of a clinical trial, how the new drugs will work, and how patients may respond to therapeutics.
